Specific protein degradation is being explored instead tactic in cancer, whereby the normal protein degradation system is co-opted for therapeutic purposes. Just lately developed novel molecules known as proteolysis-focusing on chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. One ligand binds into the ‘protein of desire’ https://www.directivepublications.org/journal-of-clinical-breast-cancer/